Health Care·Biotechnology·$2.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about ongoing market challenges. They emphasized a commitment to operational improvements but did not offer specific future guidance.
Management did not provide specific guidance for future quarters.
The company is focused on improving operational efficiencies.
Challenges in the market continue to impact performance.
ADMA Biologics reported a loss per share of $0.33, which did not meet any consensus expectations. The stock reacted negatively, declining by 0.35%. The lack of revenue details and future guidance may have contributed to investor caution.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OCCIDENTAL PETE CORP
Nov 5, 2018